Immunotherapeutics
Personalized Cancer Vaccines
TriLink manufactures messenger RNA (mRNA) based personalized cancer vaccines, as well as the plasmids used to produce them. These are one-of-a-kind medicines designed to specifically target neoantigens present in an individual patient's unique tumors. In some cases, self-replicating mRNAs based on viruses, such as alphaviruses, are used as vectors for expressing neoantigens.
CAR T-cells
TriLink manufactures Cas9, zinc-finger nuclease, and Transcription activator-like effector nuclease (TALEN) mRNAs, which are used to produce Chimeric Antigen T-cell therapies. These nucleases cause a double stranded break at a specific genomic location. A donor template encoding the chimeric antigen receptor is then inserted at the cut site by homologous recombination.